

August 9, 2007

To the Editor

For the benefit of patients and physicians Genzyme would like to clarify the current situation regarding FDA approval of large-scale manufacturing for Myozyme, our therapy for Pompe disease.

Genzyme is working closely and constructively with the US Food and Drug Administration to obtain approval of the large-scale manufacturing process to supply the US market. As typically happens in such reviews, the Agency has asked for additional information, which we will supply in the coming months. We anticipate approval of our large-scale manufacturing process in the first half of 2008.

Because Pompe is a life-threatening disease, Genzyme has been working diligently with patients, physicians and the FDA to manage our existing US supply during this review period, and to help ensure that we are able to treat the most severe, life-threatening cases.

In collaboration with the FDA, we have implemented a program to provide therapy to these patients free of charge. This program employs Myozyme produced from the large-scale manufacturing process that is currently approved in 33 countries throughout the world, but not yet in the US. We are confident based on all available data – including the clinical experience of more than 500 patients currently benefiting from Myozyme produced at this larger scale – that there is no difference in the safety or effectiveness of the two sources.

We will continue to work closely with FDA, patients and physicians to ensure patients have access to the medicine they need.

David Meeker, MD
President, Lysosomal Storage Disorder Therapeutics
Genzyme Corporation